Home Biosimilar Antibodies Others Others Dinutuximab (Anti-GD2)
For research use only. Not for use in humans.

Dinutuximab (Anti-GD2)

Synonyms: GD2 ganglioside， Disialoganglioside GD2

Dinutuximab (Anti-GD2) is a chimeric mouse/human monoclonal antibody that targets ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. It has potential antineoplastic activity. MW: 145.5 KD.

Dinutuximab (Anti-GD2)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Mechanism of Action

Description
Dinutuximab (Anti-GD2) is a chimeric mouse/human monoclonal antibody that targets ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. It has potential antineoplastic activity. MW: 145.5 KD.

Product Details

CAS No. 1363687-32-4 
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07688252 NOT_YET_RECRUITING Drug: Induction chemotherapy High Risk Neuroblastoma Chang Gung Memorial Hospital 2026-07-01 PHASE1
NCT07261241 NOT_YET_RECRUITING Drug: Radiation: 131I-MIBG|Drug: Dinutuximab|Drug: Vorinosta Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium 2026-12-31 PHASE2
NCT07334301 RECRUITING Drug: Bevacizumab|Drug: Dinutuximab beta|Drug: Irinotecan (d Relapsed Neuroblastoma University of Birmingham 2024-11-11 PHASE1; PHASE2
NCT03126916 RECRUITING Drug: Busulfan|Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclo Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma Children's Oncology Group 2018-05-14 PHASE3
NCT06485947 RECRUITING Drug: chemotherapy treatment called GPOH|Drug: chemotherapy Neuroblastoma Princess Maxima Center for Pediatric Oncology 2025-01-28 PHASE1
NCT06172296 RECRUITING Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Dru Ganglioneuroblastoma, Nodular; Neuroblastoma National Cancer Institute (NCI) 2024-04-19 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-07-07)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.